We are interested in in-licensing novel therapeutic antibody candidates, especially those targeting at tumor associated antigens. We are also exploring various techniques and joint research in cancer biology for novel targets. In addition, we are also interested in accessing technologies that would facilitate our inhouse antibody discovery and engineering activities.
Based on the nature of T-cell retargeting therapies, LintonPharm’s pipeline products are open for combo therapy collaborations. Particularly the therapeutics that would have synergies in mechanism of action, which would boost the outcome of cancer immunotherapy, for example the check point inhibitors.